Novo Is On Track To File Liraglutide For Obesity By 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk reported positive data from a Phase III trial of liraglutide in sleep apnea, completing the drug’s clinical program in obesity. It expects to file for regulatory approval of the drug as a weight reducer by year end.